Xeris Biopharma (NASDAQ:XERS) Sets New 52-Week High Following Analyst Upgrade

Key Points

• Xeris Biopharma reached a new 52-week high, trading as high as $16.35 after Barclays raised its price target from $14 to $18 and maintained an Overweight rating.
• Analyst sentiment is broadly positive: the stock has a consensus “Moderate Buy” rating and an average price target of $17, with individual targets ranging from $16 to $21.
• Xeris reported quarterly EPS of $0.06, beating the $0.03 consensus, and revenue of $107.23 million versus estimates of $101.68 million.

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) hit a new 52-week high on Wednesday after Barclays raised their price target on the stock from $14.00 to $18.00. Barclays currently has an overweight rating on the stock. Xeris Biopharma traded as high as $16.35 and last traded at $16.2060, with a volume of 277,899 shares changing hands. The stock had previously closed at $15.83.

A number of other research analysts have also recently issued reports on the stock. Leerink Partners lifted their price objective on shares of Xeris Biopharma from $12.00 to $16.00 and gave the company an "outperform" rating in a research note on Thursday, September 10th. HC Wainwright raised their target price on Xeris Biopharma from $10.00 to $18.00 and gave the company a "buy" rating in a report on Friday, November 6th. Wall Street Zen upgraded Xeris Biopharma from a "buy" rating to a "strong-buy" rating in a research note on Saturday. Weiss Ratings reissued a "sell (d-)" rating on shares of Xeris Biopharma in a report on Wednesday, November 4th. Finally, Oppenheimer reissued an "outperform" rating and set a $21.00 price target (up from $18.00) on shares of Xeris Biopharma in a report on Friday, November 6th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Xeris Biopharma presently has an average rating of "Moderate Buy" and a consensus target price of $17.00.

Insiders Place Their Bets

In related news, insider Beth Hecht sold 25,000 shares of the company's stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $10.23, for a total value of $255,750.00. Following the sale, the insider directly owned 1,086,130 shares in the company, valued at $11,111,109.90. This represents a 2.25% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin McCulloch sold 25,000 shares of Xeris Biopharma stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $12.49, for a total transaction of $312,250.00. Following the transaction, the insider directly owned 1,559,208 shares of the company's stock, valued at $19,474,507.92. This represents a 1.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 168,332 shares of company stock valued at $1,678,971 in the last ninety days. 4.35% of the stock is currently owned by insiders.

Xeris Biopharma News Roundup

Here's some of the latest news about XERS:

• Positive Sentiment: HC Wainwright reiterated its “Buy” rating and $18 price target while raising its earnings forecasts: FY2026 EPS to $0.14 from $0.04, FY2027 to $0.13 from $0.11, and FY2030 to $1.03 from $0.92. The higher longer-term outlook suggests improved expectations for earnings growth. Xeris Biopharma coverage
• Positive Sentiment: Wall Street Zen upgraded Xeris, and a separate brokerage roundup characterized the stock’s consensus rating as “Moderate Buy.” These ratings add to the favorable analyst tone. Wall Street Zen upgrade Brokerage ratings
• Neutral Sentiment: The short-interest item calls the change a “large increase” but reports zero shares short as of November 10. Because those details conflict, it offers no clear signal about short-selling pressure or potential short covering.

Institutional Trading of Xeris Biopharma

Large investors have recently made changes to their positions in the company. BlackRock Inc. bought a new position in Xeris Biopharma in the 2nd quarter valued at about $115,042,000. Wellington Management Group LLP lifted its holdings in shares of Xeris Biopharma by 8.9% in the second quarter. Wellington Management Group LLP now owns 2,365,103 shares of the company's stock valued at $18,732,000 after purchasing an additional 193,749 shares in the last quarter. Legal & General Group Plc purchased a new position in shares of Xeris Biopharma during the second quarter valued at approximately $15,941,000. Parkman Healthcare Partners LLC purchased a new position in shares of Xeris Biopharma during the second quarter valued at approximately $14,316,000. Finally, Algert Global LLC grew its holdings in Xeris Biopharma by 50.6% during the second quarter. Algert Global LLC now owns 1,742,942 shares of the company's stock worth $13,804,000 after buying an additional 585,984 shares in the last quarter. 42.75% of the stock is currently owned by institutional investors and hedge funds.

Xeris Biopharma Price Performance

The firm has a market cap of $2.95 billion, a P/E ratio of -321.80 and a beta of 0.61. The company has a fifty day moving average of $9.92 and a 200-day moving average of $7.70. The company has a debt-to-equity ratio of 3.89, a current ratio of 2.15 and a quick ratio of 1.02.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported $0.06 earnings per share for the quarter, topping analysts' consensus estimates of $0.03 by $0.03. The firm had revenue of $107.23 million for the quarter, compared to the consensus estimate of $101.68 million. Xeris Biopharma had a positive return on equity of 147.75% and a negative net margin of 1.76%. On average, sell-side analysts anticipate that Xeris Biopharma Holdings, Inc. will post 0.13 EPS for the current fiscal year.

Xeris Biopharma Company Profile

Xeris Biopharma is a commercial-stage biopharmaceutical company focused on developing and providing treatments for people with endocrine and other serious health conditions. Its products include Gvoke, a ready-to-use glucagon product for the treatment of severe hypoglycemia, and Recorlev, a treatment for adults with endogenous hypercortisolemia associated with Cushing syndrome when surgery is not an option or has not been curative. The company also develops drug-delivery technologies intended to make medicines easier to store and administer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.